Literature DB >> 33716796

Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities.

Mingyang Chang1, Bohan Chen1, James Shaffner1, Lance D Dworkin1, Rujun Gong1.   

Abstract

Melanocortin peptides, melanocortin receptors, melanocortin receptor accessory proteins, and endogenous antagonists of melanocortin receptors are the key components constituting the melanocortin hormone system, one of the most complex and important hormonal systems in our body. A plethora of evidence suggests that melanocortins possess a protective activity in a variety of kidney diseases in both rodent models and human patients. In particular, the steroidogenic melanocortin peptide adrenocorticotropic hormone (ACTH), has been shown to exert a beneficial effect in a number of kidney diseases, possibly via a mechanism independent of its steroidogenic activity. In patients with steroid-resistant nephrotic glomerulopathy, ACTH monotherapy is still effective in inducing proteinuria remission. This has inspired research on potential implications of the melanocortin system in glomerular diseases. However, our understanding of the role of the melanocortinergic pathway in kidney disease is very limited, and there are still huge unknowns to be explored. The most controversial among these is the identification of effector cells in the kidney as well as the melanocortin receptors responsible for conveying the renoprotective action. This review article introduces the melanocortin hormone system, summarizes the existing evidence for the expression of melanocortin receptors in the kidney, and evaluates the potential strategy of melanocortin therapy for kidney disease.
Copyright © 2021 Chang, Chen, Shaffner, Dworkin and Gong.

Entities:  

Keywords:  adrenocorticotropic hormone; glomerulus; kidney disease; melanocortin receptors; melanocyte-stimulating hormone; pro-opiomelanocortin

Year:  2021        PMID: 33716796      PMCID: PMC7943476          DOI: 10.3389/fphys.2021.651236

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


  84 in total

1.  Melanocortin-2 receptor accessory protein MRAP forms antiparallel homodimers.

Authors:  Julien A Sebag; Patricia M Hinkle
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

Review 2.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

Review 3.  Targeting podocyte-associated diseases.

Authors:  Jan Willem Leeuwis; Tri Q Nguyen; Amélie Dendooven; Robbert J Kok; Roel Goldschmeding
Journal:  Adv Drug Deliv Rev       Date:  2010-09-07       Impact factor: 15.470

4.  Interaction of dual intracellular signaling pathways activated by the melanocortin-3 receptor.

Authors:  Y Konda; I Gantz; J DelValle; Y Shimoto; H Miwa; T Yamada
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

Review 5.  Inducible rodent models of acquired podocyte diseases.

Authors:  Jeffrey W Pippin; Paul T Brinkkoetter; Fionnualla C Cormack-Aboud; Raghu V Durvasula; Peter V Hauser; Jolanta Kowalewska; Ronald D Krofft; Christine M Logar; Caroline B Marshall; Takamoto Ohse; Stuart J Shankland
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-10

6.  Crucial role of the melanocortin receptor MC1R in experimental colitis.

Authors:  C Maaser; K Kannengiesser; C Specht; A Lügering; T Brzoska; T A Luger; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

Review 7.  alpha-Melanocyte-stimulating hormone and acute renal failure.

Authors:  Y Kohda; H Chiao; R A Star
Journal:  Curr Opin Nephrol Hypertens       Date:  1998-07       Impact factor: 2.894

8.  Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model.

Authors:  D A C Botte; I L Noronha; D M A C Malheiros; T V Peixoto; S B V de Mello
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

9.  Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.

Authors:  Andrew S Bomback; James A Tumlin; Joel Baranski; James E Bourdeau; Anatole Besarab; Alice S Appel; Jai Radhakrishnan; Gerald B Appel
Journal:  Drug Des Devel Ther       Date:  2011-03-14       Impact factor: 4.162

10.  Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series.

Authors:  Arvind Madan; Snezana Mijovic-Das; Ana Stankovic; Geoffrey Teehan; Amber S Milward; Anupa Khastgir
Journal:  BMC Nephrol       Date:  2016-03-31       Impact factor: 2.388

View more
  1 in total

Review 1.  How immunosuppressive drugs may directly target podocytes in glomerular diseases.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  Pediatr Nephrol       Date:  2021-07-09       Impact factor: 3.651

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.